Patents

US 9624526 B2: Method for treating pervasive development disorders

Granted
2017-04-18
Filed
2011-12-07 application 13313708
Type
Utility · 15 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

Source: PVGPATDIS, file of 2026-04-10 (ipg170418.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
CUREMARK, LLC 55 patentsUS company or organizationRye, NYCUREMARK, LLC State business registration EXACT high confidence: identical full name and state
CUREMARK LLC Form D issuer EXACT high confidence: identical full name and state
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Joan M. FallonBronxville, NY61PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K38/4826PVGPATDIS, file of 2026-04-10
A61BDiagnosis; surgery; identificationA61B5/1118PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/18PVGPATDIS, file of 2026-04-10
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12Q1/37PVGPATDIS, file of 2026-04-10
C12YEnzymesC12Y302/0102PVGPATDIS, file of 2026-04-10
G01NInvestigating or analysing materials by determining their chemical or physical propertiesG01N2333/976PVGPATDIS, file of 2026-04-10
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digestsY10S435/803PVGPATDIS, file of 2026-04-10
Y10TTechnical subjects covered by former us classificationY10T436/24PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2017-02-09Correction
Corrective assignment to correct the receiving party data previously recorded at reel: 032959 frame: 0715. assignor(s) hereby confirms the assignment.
FALLON, JOAN M. signed 2009-08-31CUREMARK, LLC RYE, CA41671/484ECORSEXC, file of 2026-09-25
2014-05-23Assignment
Assignment of assignor's interest
FALLON, JOAN M. signed 2009-08-31CUREMARK LLC RYE, NY32959/715ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.